TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Drug Therapy Lung Neoplasms Carcinoma, Non-Small-Cell Lung Cisplatin Carboplatin Pemetrexed TAK-788
Lead Scientist at UCSD
- Lyudmila Bazhenova
Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators.
- accepting new patients
- Start Date
- Completion Date
- Millennium Pharmaceuticals, Inc.
- Phase 3
- Study Type
- Last Updated